ARWR241220P16000
- 0.05
- -0.03-37.50%
Arrowhead Pharmaceuticals Newsroom
Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Arrowhead Pharmaceuticals Price Target Raised to $80.00/Share From $60.00 by HC Wainwright & Co.
Arrowhead Pharma Analyst Ratings
Arrowhead Pharmaceuticals Files Request to Initiate Phase 1/2a Trial of Obesity Treatment
Express News | Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of Aro-Alk7 for the Treatment of Obesity
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Trending Stocks This Week as Holiday Season Begins With Thanksgiving Break
Express News | Bernstein Maintains Market Perform on Arrowhead Pharma, Lowers Price Target to $24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR) and Sanofi (OtherSNYNF)
Arrowhead Pharmaceuticals Faces Distribution Risks With Vanscoy Reliance
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
Arrowhead Pharmaceuticals Is Maintained at Neutral by Citigroup
Express News | Arrowhead Pharmaceuticals Shares up 6.2% ; at Least Two Brokerages Raise PT After Licensing Deal With Sarepta
Arrowhead Pharmaceuticals Shares Are Trading Higher. Chardan Capital Maintained a Buy Rating on the Stock.
Express News | Arrowhead Pharmaceuticals Shares Are Trading Higher. Chardan Capital Maintained a Buy Rating on the Stock
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $42
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $45
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $26 to $45